ZEAL — Zealand Pharma A/S Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapMomentum Trap

Annual income statement for Zealand Pharma A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.

	C2019 December 31st	R2020 December 31st	R2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	Interim Report	ARS	ARS
Standards:	IFRS	IFRS	—	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	41.3	192	109	104	343
Cost of Revenue
Gross Profit	40.9	192	97.6	104	324
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	629	818	893	1,064	1,051
Operating Profit	-588	-626	-784	-960	-708
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-577	-674	-759	-972	-709
Provision for Income Taxes
Net Income After Taxes	-572	-669	-755	-966	-704
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-572	-847	-1,018	-1,202	-704
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-572	-847	-1,018	-1,202	-704
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-16.9	-17.4	-17.6	-18.3	-10.8
Dividends per Share